Tirzepatide 60-week results: what the clinical evidence actually shows

What the trial data looked like approaching 60 weeks

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and no diabetes, following them for 72 weeks. The 60-week period is clinically significant because it represents the phase when participants had generally been on their highest tolerated dose for at least two to three months, the point at which weight loss curves begin to plateau toward their final values.

Average weight reduction across all three active doses was well above 10% by this stage. At the highest dose of 15mg, the eventual 72-week figure reached approximately 20–21%, with some analyses reporting higher. The 60-week results fed directly into NICE's assessment: NICE TA1026's recommendations chapter cites the SURMOUNT programme as the core evidence base and sets out which adults are eligible on the NHS. Those results also underpin the private-prescription eligibility criteria, adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia or obstructive sleep apnoea.

One thing worth noting: the 60-week data reflects consistent dosing, lifestyle support, and regular clinical review throughout. Trial conditions are controlled; real-world outcomes vary. That context matters when reading any headline figure.

Why the titration schedule means 60 weeks covers a lot of ground

Tirzepatide treatment does not begin at a therapeutic dose. The first pen is 2.5mg, a level chosen to help the body adjust rather than to produce significant weight loss immediately. Doses increase in approximately four-week steps (2.5mg, then 5mg, 7.5mg, 10mg, 12.5mg, up to 15mg) so by week 60, most patients who tolerated the medicine well have spent the majority of their time at 10mg, 12.5mg or 15mg.

This is why the 60-week window matters: it is largely a maintenance-phase snapshot rather than a ramp-up-phase one. The body's response to the medicine is better established, appetite suppression is more consistent, and weight loss has slowed from its early rapid pace to a steadier rate. For anyone wondering whether treatment is still working at this stage, slower loss is normal and expected, it is not the same as the medicine stopping. A prescriber can review progress and discuss whether continuing, adjusting, or pausing makes clinical sense.

If you want a fuller picture of how the doses and schedule fit together, our tirzepatide overview covers the mechanism and licensed UK strengths in detail, and you can also read specifically about tirzepatide 30 if you want to understand how the supply format relates to a month of treatment at the higher end of the dose range.

Side effects at the 60-week mark: what the evidence shows

Most gastrointestinal side effects (nausea, loose stools, indigestion, reflux) are most common in the first weeks after starting or increasing a dose. By 60 weeks, the majority of participants who experienced them had seen them settle. That pattern is consistent with what the NHS tirzepatide medicines page describes: GI effects tend to ease once the body has adjusted to a stable dose.

That said, side effects did not disappear entirely for everyone at 60 weeks. Some participants reported persistent nausea at higher doses, and a small proportion did not reach 15mg for this reason. Any side effect that is severe, persistent, or new after a long period of stability (particularly severe abdominal pain) warrants prompt medical attention. The MHRA issued specific guidance in January 2026 highlighting acute pancreatitis as a known but infrequent risk with GLP-1 medicines; severe stomach pain radiating to the back is a signal to seek help the same day.

Injection-site rotation (abdomen, thigh, upper arm) remains relevant throughout treatment, including at 60 weeks and beyond, to reduce localised reactions.

What 60 weeks of evidence means if you are considering tirzepatide now

For most people researching tirzepatide, the 60-week question is really a question about staying power: does it keep working, and is it worth committing to? The evidence says yes, weight reduction is maintained in most participants who continue treatment through to 72 weeks, and NICE's recommendation reflects that durability.

The private route is straightforward if NHS criteria do not apply to you or the waiting time is too long. Some people find it useful to order before the end of the month when payday lines up with a Monday, so the same-day clinical review and next-working-day dispatch happen without any gap. Either way, there is no waiting list with a regulated online pharmacy. You can read about Mounjaro (tirzepatide's UK brand name) in more detail, or compare the available treatment options on the weight loss treatments overview.

If you would like to understand how tirzepatide sits alongside other licensed options, this page on Mounjaro vs tirzepatide clarifies the naming and licensing picture. For questions about cost and what a private prescription includes, the tirzepatide pricing context page sets out what legitimate treatment covers. And if you are weighing up whether to proceed with a prescription, the consultation is free and carries no obligation. A named prescriber (not a piece of software) reads your answers and makes the clinical call. That is how it works at nume.

When you are ready, start your free consultation and our prescribers will assess your suitability the same day.